These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 16848688)

  • 21. [Immunotherapy targeting misfolded proteins in neurodegenerative disease].
    Kanemaru K
    Brain Nerve; 2013 Apr; 65(4):469-74. PubMed ID: 23568995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurodegenerative disorders and sterile inflammation: lessons from a Drosophila model.
    Nainu F; Salim E; Asri RM; Hori A; Kuraishi T
    J Biochem; 2019 Sep; 166(3):213-221. PubMed ID: 31251338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformational diseases: structural studies of aggregation of polyglutamine proteins.
    Papaleo E; Invernizzi G
    Curr Comput Aided Drug Des; 2011 Mar; 7(1):23-43. PubMed ID: 20807186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polyglutamine protein aggregates are dynamic.
    Kim S; Nollen EA; Kitagawa K; Bindokas VP; Morimoto RI
    Nat Cell Biol; 2002 Oct; 4(10):826-31. PubMed ID: 12360295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of molecular chaperones in neurodegenerative disorders.
    Meriin AB; Sherman MY
    Int J Hyperthermia; 2005 Aug; 21(5):403-19. PubMed ID: 16048838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.
    Nagai Y; Fujikake N; Popiel HA; Wada K
    Curr Pharm Biotechnol; 2010 Feb; 11(2):188-97. PubMed ID: 20166962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of neurodegeneration by molecular chaperones.
    Muchowski PJ; Wacker JL
    Nat Rev Neurosci; 2005 Jan; 6(1):11-22. PubMed ID: 15611723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toward an understanding of polyglutamine neurodegeneration.
    Paulson HL
    Brain Pathol; 2000 Apr; 10(2):293-9. PubMed ID: 10764049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
    Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
    Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis.
    Wyttenbach A
    J Mol Neurosci; 2004; 23(1-2):69-96. PubMed ID: 15126694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting chaperones, heat shock factor-1, and unfolded protein response: Promising therapeutic approaches for neurodegenerative disorders.
    Bose S; Cho J
    Ageing Res Rev; 2017 May; 35():155-175. PubMed ID: 27702699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aggregation formation in the polyglutamine diseases: protection at a cost?
    Todd TW; Lim J
    Mol Cells; 2013 Sep; 36(3):185-94. PubMed ID: 23794019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aptamer and its applications in neurodegenerative diseases.
    Qu J; Yu S; Zheng Y; Zheng Y; Yang H; Zhang J
    Cell Mol Life Sci; 2017 Feb; 74(4):683-695. PubMed ID: 27563707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detecting and targeting neurodegenerative disorders using electrospun nanofibrous matrices: current status and applications.
    Siafaka PI; Özcan Bülbül E; Dilsiz P; Karantas ID; Okur ME; Üstündağ Okur N
    J Drug Target; 2021 Jun; 29(5):476-490. PubMed ID: 33269637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders.
    Ross CA
    Neuron; 2002 Aug; 35(5):819-22. PubMed ID: 12372277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein precipitation: a common etiology in neurodegenerative disorders?
    Kakizuka A
    Trends Genet; 1998 Oct; 14(10):396-402. PubMed ID: 9820028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting TRPs in neurodegenerative disorders.
    Takada Y; Numata T; Mori Y
    Curr Top Med Chem; 2013; 13(3):322-34. PubMed ID: 23432063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ageing and protein aggregation-mediated disorders: from invertebrates to mammals.
    Dillin A; Cohen E
    Philos Trans R Soc Lond B Biol Sci; 2011 Jan; 366(1561):94-8. PubMed ID: 21115535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM; Fischer DF; Ovaa H; Scheper W
    Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small molecule enhancers of autophagy for neurodegenerative diseases.
    Sarkar S; Rubinsztein DC
    Mol Biosyst; 2008 Sep; 4(9):895-901. PubMed ID: 18704227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.